|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Real-World Treatments Following BCG Induction in Patients with NMIBC: A US Claims Analysis |
| Amanda Myers, MD |
| Zachary Klaassen and Amanda Myers discuss a US claims analysis examining real-world treatment patterns following BCG induction in non-muscle invasive bladder cancer patients. The study reveals significant underutilization of maintenance BCG therapy, with only a quarter of patients receiving adequate maintenance doses after induction. |
|
|
|
|
|
|
|
|
|
|
|
|
Real-World Data on Nadofarogene Firadenovec for BCG-Unresponsive Bladder Cancer
|
Mark Tyson II, MD, MPH, and Jacob Moyer, BS
Mark Tyson and Jacob Moyer discuss real-world experience with nadofarogene firadenovec in BCG-unresponsive NMIBC. Drawing from data across three Mayo Clinic sites, they report encouraging response rates that align with or exceed clinical trial results, including 79% complete response in CIS patients and 68% in papillary-only disease at three months. |
|
|
|
|
|
|
|
|
|
|
| Real-World Effectiveness of Enfortumab Vedotin in Advanced Urothelial Carcinoma |
| Umang Swami, MD |
| Alicia Morgans speaks with Umang Swami about a publication in Clinical Genitourinary Cancer examining the real-world effectiveness of enfortumab vedotin (EV) in advanced urothelial carcinoma. Using the Flatiron Health database, which includes data from 280 US cancer clinics, the study analyzes outcomes for 371 patients receiving EV as second-line therapy or beyond. |
|
|
|
|
|
|
|
|
|
|
|
| Real-World Treatments Following BCG Induction in Patients with NMIBC: A Contemporary US Claims Analysis
|
| Amanda Myers, MD
|
| Amanda Myers presented a real-world analysis at SCS AUA 2024 on treatment patterns following BCG induction in NMIBC patients using a US insurance claims database. Among 7,058 patients receiving BCG, 63.4% had adequate induction, but only 24.9% received adequate maintenance BCG, with significant variation in subsequent treatments, including further BCG, other therapies, and no further treatment.
|
|
|
|
|
|
| Real-World Outcomes of Nadofaragene Firadenovec in BCG-Unresponsive NMIBC |
| Jacob Moyer, BS |
| Jacob Moyer presented real-world outcomes of nadofaragene firadenovec in BCG-unresponsive NMIBC at ASCO GU 2025, showing promising efficacy and safety data. Among 24 evaluable CIS patients, 79% achieved a complete response at 3 months, with 84% maintaining response at a median follow-up of 7.3 months, while 68% of papillary-only patients were recurrence-free at 3 months. |
|
|
|
|
|
| Postoperative Adjuvant Treatment of HER2 Overexpression in Upper Urinary Tract Urothelial Carcinoma with the Combination of Disitamab Vedotin and Toripalimab: A Real-World Retrospective Study |
| Shun Zhang, MD |
| Shun Zhang presented a real-world retrospective study evaluating the combination of disitamab vedotin and toripalimab as adjuvant therapy in HER2-overexpressing upper urinary tract urothelial carcinoma after radical nephroureterectomy. Among 36 patients, those receiving the combination therapy had a significantly higher 12-month disease-free survival rate with no Grade 3 or higher adverse events. |
|
|
|
|
|
|
|
|
|
|
| Global Real-World Patients Characteristics, Treatment Patterns, and Impact of BCG Shortage in Patients with High-Risk Non-Muscle Invasive Bladder Cancer
|
| Jens Bedke, MD
|
| A global real-world study examined patient characteristics, treatment patterns, and the impact of BCG shortages in high-risk, non-muscle invasive bladder cancer across 1,930 patients. Results showed that while BCG remains the standard of care, most patients do not receive the full recommended maintenance course, with 39% receiving no BCG at all—primarily due to patient refusal and global shortages.
|
|
|
|
|
|
| Clinical Characteristics and Treatment Patterns of Patients with Muscle Invasive Bladder Cancer: A Real-World Cohort Study |
| John Gore, MD, MS |
| John Gore presented a real-world cohort study at ASCO GU 2025 analyzing clinical characteristics and treatment patterns in MIBC patients using claims data from 2020-2021. Among 332 patients, 41% did not receive neoadjuvant therapy, and only 12% received adjuvant therapy, with immunotherapy being the most common adjuvant treatment. The study highlighted the need for further evaluation of evolving treatment strategies, as many MIBC patients undergo radical cystectomy without systemic therapy despite current guidelines. |
|
|
|
|
|
| Real-World Effectiveness and Safety of Avelumab First-Line Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Second Interim Analysis of the AVENUE Study |
| Peter Goebell, MD, PhD |
| The AVENUE study confirms the real-world effectiveness and safety of avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma, showing outcomes consistent with the JAVELIN Bladder 100 trial. At a 10-month median follow-up, the 6- and 12-month overall survival rates were 80.6% and 69.1%, respectively, with a median PFS of 5.8 months. |
|
|
|
|
|
| Real-World Analysis of the Efficacy and Safety of Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study |
| Shingo Hatakeyama, MD |
| A real-world, multicenter retrospective study evaluated enfortumab vedotin (EV) in locally advanced or metastatic urothelial carcinoma across 419 patients. Results showed that patients receiving EV after chemotherapy and immunotherapy (chemo-ICI-EV group) had significantly longer overall survival compared to other treatment groups. |
|
|
|
|
|
| Real-World Time on Treatment with First-Line Enfortumab Vedotin and Pembrolizumab After U.S. FDA Approval for Advanced Urothelial Cancer |
| Aram Babcock, PharmD, MS, MBA |
| A real-world analysis examined time on treatment with first-line enfortumab vedotin + pembrolizumab in advanced urothelial carcinoma after its FDA approval. Among 111 patients, the median time on treatment was 8.1 months, aligning with EV-302 trial data, with 41.4% discontinuing therapy and 24% starting second-line treatment. While most patients followed standard dosing schedules, variations increased after three cycles, highlighting the need for further data on long-term real-world outcomes. |
|
|
|
|
|
| Real-World Toxicity Profile of Enfortumab Vedotin with or Without Pembrolizumab in Ultra-Elderly Urothelial Carcinoma Patients
|
| Nataliya Mar, MD
|
| Nataliya Mar presented a retrospective analysis which evaluated the real-world toxicity of enfortumab vedotin ± pembrolizumab in ultra-elderly urothelial carcinoma patients. Among 26 patients, 50% required dose reductions, 42.3% had dose delays, and 30.8% discontinued treatment due to adverse events. Neuropathy and ocular toxicity were the most common toxicities.
|
|
|
|
|
|
| Clinical Efficacy of Enfortumab Vedotin + Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma: A Real-World Retrospective Study |
| Prateek Jain, MD, MS |
| A real-world retrospective study presented at ASCO GU 2025 evaluated the clinical efficacy of enfortumab vedotin + pembrolizumab in 120 patients with locally advanced or metastatic urothelial carcinoma. Results showed a median progression-free survival of 12.7 months and median overall survival of 25.1 months, with 46.6% of patients achieving a partial response and 28.3% achieving a complete response. |
|
|
|
|
|
|
|
|
|
|
